363 related articles for article (PubMed ID: 35986846)
1. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
[TBL] [Abstract][Full Text] [Related]
3. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
[TBL] [Abstract][Full Text] [Related]
4. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
[TBL] [Abstract][Full Text] [Related]
5. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y;
J Gastroenterol Hepatol; 2023 Aug; 38(8):1389-1397. PubMed ID: 37231943
[TBL] [Abstract][Full Text] [Related]
6. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853
[TBL] [Abstract][Full Text] [Related]
7. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Chiang CL; Chan SK; Lee SF; Choi HC
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Kuroda H; Yata Y; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Yokohama K; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; ;
Oncology; 2023; 101(10):624-633. PubMed ID: 37307798
[TBL] [Abstract][Full Text] [Related]
9. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Gordan JD; Kennedy EB; Abou-Alfa GK; Beal E; Finn RS; Gade TP; Goff L; Gupta S; Guy J; Hoang HT; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Kortmansky J; Leaf A; Remak WM; Sohal DPS; Taddei TH; Wilson Woods A; Yarchoan M; Rose MG
J Clin Oncol; 2024 May; 42(15):1830-1850. PubMed ID: 38502889
[TBL] [Abstract][Full Text] [Related]
11. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y
Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060
[TBL] [Abstract][Full Text] [Related]
13. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
[TBL] [Abstract][Full Text] [Related]
14. Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
Singal AG; Özgürdal K; Fan X; Vassilev Z; Pan X; Multani JK; Chen CC; Zhou Z; He J; Pisa F
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067235
[TBL] [Abstract][Full Text] [Related]
15. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
[TBL] [Abstract][Full Text] [Related]
16. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T; Higashi S; Abe Y; Mukai K; Ikawa T; Konishi K; Maeda N; Nakanishi K; Hasegawa S; Wada H; Ohkawa K
Curr Oncol; 2024 Mar; 31(3):1543-1555. PubMed ID: 38534950
[TBL] [Abstract][Full Text] [Related]
17. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Chihiro K; Kawaoka T; Uchikawa S; Kinami T; Yamasaki S; Kosaka M; Johira Y; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Teraoka Y; Uchida T; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Imamura M; Aikata H; Oka S
Oncology; 2023; 101(8):491-501. PubMed ID: 37429266
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359
[TBL] [Abstract][Full Text] [Related]
19. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
20. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
Gordan JD; Kennedy EB; Abou-Alfa GK; Beg MS; Brower ST; Gade TP; Goff L; Gupta S; Guy J; Harris WP; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Knox JJ; Kortmansky J; Leaf A; Remak WM; Shroff RT; Sohal DPS; Taddei TH; Venepalli NK; Wilson A; Zhu AX; Rose MG
J Clin Oncol; 2020 Dec; 38(36):4317-4345. PubMed ID: 33197225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
